Cargando…

Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics

Cystic fibrosis is realizing the promise of personalized medicine. Recent advances in drug development that target the causal CFTR directly result in lung function improvement, but variability in response is demanding better prediction of outcomes to improve management decisions. The genetic modifie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strug, Lisa J., Gonska, Tanja, He, Gengming, Keenan, Katherine, Ip, Wan, Boëlle, Pierre-Yves, Lin, Fan, Panjwani, Naim, Gong, Jiafen, Li, Weili, Soave, David, Xiao, Bowei, Tullis, Elizabeth, Rabin, Harvey, Parkins, Michael D., Price, April, Zuberbuhler, Peter C., Corvol, Harriet, Ratjen, Felix, Sun, Lei, Bear, Christine E., Rommens, Johanna M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2016
Materias:	Association Studies Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5886039/ https://www.ncbi.nlm.nih.gov/pubmed/28171547 http://dx.doi.org/10.1093/hmg/ddw290

Ejemplares similares

A Joint Location-Scale Test Improves Power to Detect Associated SNPs, Gene Sets, and Pathways
por: Soave, David, et al.
Publicado: (2015)

LocusFocus: Web-based colocalization for the annotation and functional follow-up of GWAS
por: Panjwani, Naim, et al.
Publicado: (2020)

Improving imputation in disease-relevant regions: lessons from cystic fibrosis
por: Panjwani, Naim, et al.
Publicado: (2018)

Genetic association and transcriptome integration identify contributing genes and tissues at cystic fibrosis modifier loci
por: Gong, Jiafen, et al.
Publicado: (2019)

Weight increase in people with cystic fibrosis on CFTR modulator therapy is mainly due to increase in fat mass
por: Mouzaki, Marialena, et al.
Publicado: (2023)

The CFTR Mutation c.3453G > C (D1152H) Confers an Anion Selectivity Defect in Primary Airway Tissue that Can be Rescued by Ivacaftor
por: Laselva, Onofrio, et al.
Publicado: (2020)

Evidence for a Causal Relationship Between Early Exocrine Pancreatic Disease and Cystic Fibrosis–Related Diabetes: A Mendelian Randomization Study
por: Soave, David, et al.
Publicado: (2014)

Genetic evidence supports the development of SLC26A9 targeting therapies for the treatment of lung disease
por: Gong, Jiafen, et al.
Publicado: (2022)

Phenotypic profiling of CFTR modulators in patient-derived respiratory epithelia
por: Ahmadi, Saumel, et al.
Publicado: (2017)

SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis
por: Corvol, Harriet, et al.
Publicado: (2018)

Validating organoid-derived human intestinal monolayers for personalized therapy in cystic fibrosis
por: Birimberg-Schwartz, Liron, et al.
Publicado: (2023)

Orkambi® and amplifier co‐therapy improves function from a rare CFTR mutation in gene‐edited cells and patient tissue
por: Molinski, Steven V, et al.
Publicado: (2017)

High-quality read-based phasing of cystic fibrosis cohort informs genetic understanding of disease modification
por: Mastromatteo, Scott, et al.
Publicado: (2022)

Directed differentiation of human pluripotent stem cells into mature airway epithelia expressing functional CFTR protein
por: Wong, Amy P., et al.
Publicado: (2012)

Preclinical Studies of a Rare CF-Causing Mutation in the Second Nucleotide Binding Domain (c.3700A>G) Show Robust Functional Rescue in Primary Nasal Cultures by Novel CFTR Modulators
por: Laselva, Onofrio, et al.
Publicado: (2020)

A flexible summary statistics-based colocalization method with application to the mucin cystic fibrosis lung disease modifier locus
por: Wang, Fan, et al.
Publicado: (2022)

Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator
por: Laselva, Onofrio, et al.
Publicado: (2021)

Gene Therapy: A Possible Alternative to CFTR Modulators?
por: Mercier, J., et al.
Publicado: (2021)

Immunoreactive trypsinogen levels in newborn screened infants with an inconclusive diagnosis of cystic fibrosis
por: Ooi, Chee Y., et al.
Publicado: (2019)

Associations
Publicado: (1860)

Impact of CFTR modulation with Ivacaftor on Gut Microbiota and Intestinal Inflammation
por: Ooi, Chee Y., et al.
Publicado: (2018)

Correction to: Cystic fibrosis–related diabetes onset can be predicted using biomarkers measured at birth
por: Lin, Yu-Chung, et al.
Publicado: (2021)

Cystic fibrosis–related diabetes onset can be predicted using biomarkers measured at birth
por: Lin, Yu-Chung, et al.
Publicado: (2021)

Testing Calibration of Cox Survival Models at Extremes of Event Risk
por: Soave, David M., et al.
Publicado: (2018)

Correlation of Electrophysiological and Fluorescence-Based Measurements of Modulator Efficacy in Nasal Epithelial Cultures Derived from People with Cystic Fibrosis
por: Gunawardena, Tarini N. A., et al.
Publicado: (2023)

CFTR interactome mapping using the mammalian membrane two‐hybrid high‐throughput screening system
por: Lim, Sang Hyun, et al.
Publicado: (2022)

Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis
por: Corvol, Harriet, et al.
Publicado: (2015)

Phenotyping Rare CFTR Mutations Reveal Functional Expression Defects Restored by TRIKAFTA(TM)
por: Laselva, Onofrio, et al.
Publicado: (2021)

Impact of Coronavirus Disease 2019 (COVID-19) Pandemic on Pediatric Infectious Disease Research
por: Bensoussan, Eden, et al.
Publicado: (2021)

Molecular Mechanism of Action of Trimethylangelicin Derivatives as CFTR Modulators
por: Laselva, Onofrio, et al.
Publicado: (2018)

CFTR mutations altering CFTR fragmentation
por: Tosoni, Kendra, et al.
Publicado: (2012)

Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
por: Laselva, Onofrio, et al.
Publicado: (2019)

Functional Rescue of F508del-CFTR Using Small Molecule Correctors
por: Molinski, Steven, et al.
Publicado: (2012)

VikNGS: a C++ variant integration kit for next generation sequencing association analysis
por: Baskurt, Zeynep, et al.
Publicado: (2020)

Treatment of Aspergillus fumigatus in Patients with Cystic Fibrosis: A Randomized, Placebo-Controlled Pilot Study
por: Aaron, Shawn D., et al.
Publicado: (2012)

Synergy of cAMP and calcium signaling pathways in CFTR regulation
por: Bozoky, Zoltan, et al.
Publicado: (2017)

A blood pressure-associated variant of the SLC39A8 gene influences cellular cadmium accumulation and toxicity
por: Zhang, Ruoxin, et al.
Publicado: (2016)

Perspectives on the translation of in-vitro studies to precision medicine in Cystic Fibrosis
por: Dumas, Marie-Pier, et al.
Publicado: (2021)

Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients
por: Boëlle, Pierre‐Yves, et al.
Publicado: (2018)

Factors Predisposing the Response to Lumacaftor/Ivacaftor in People with Cystic Fibrosis
por: Mésinèle, Julie, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kngiro35uq27i68es54sp6ctp2